Protagonist Therapeutics, Inc. (PGF.SG)
| Previous close | 15.20 |
| Open | 38.00 |
| Bid | 15.10 x 0 |
| Ask | 15.60 x 0 |
| Day's range | 15.00 - 15.80 |
| 52-week range | 10.80 - 42.80 |
| Volume | |
| Avg. volume | 179 |
| Market cap | 726.438M |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.45 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.25 |
Simply Wall St.We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...
GlobeNewswireTurnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
PR NewswireProtagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan. The presentation, "First-in-class oral pept
